Rufinamide as an adjuvant treatment in children with Lennox-Gastaut syndrome

Shin Hye Kim, So Hee Eun, Hoon Chul Kang, Eun Ji Kwon, Jung Hye Byeon, Young Mock Lee, Joon Soo Lee, Baik Lin Eun, Heung Dong Kim

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Purpose: To evaluate the efficacy of rufinamide as an add-on treatment in children and adolescents with Lennox-Gastaut syndrome (LGS). Methods: The study was an open-label, observational clinical trial of rufinamide as an add-on treatment in intractable LGS patients. This intent-to-treat trial included 4 weeks of scheduled titrated doses and a 12-week maintenance phase with a target dose of 20-40 mg/kg rufinamide, adjusted according to its effectiveness and tolerability after a baseline period of 4 weeks. The primary outcome was measured by the seizure-reduction rate according to individual seizure type over the 12-week maintenance period. Results: One hundred and twenty-eight patients with LGS who were determined to be unresponsive to one or more antiepileptic drugs or dietary therapy were enrolled. Of the 128 patients enrolled, 112 (87.5%) completed the study. After add-on rufinamide treatment, 46 patients (35.9%) achieved a more than 50% reduction in seizure frequency and 10 (7.8%) patients became seizure-free. When we identified those who responded with an at least 50% reduction in seizure frequency, 39.4% of the responders reported reductions in convulsive seizures, 36.4% in drop attacks, 33.3% in myoclonic seizures, and 20.0% in epileptic spasms. Overall, 32.8% of patients reported adverse effects, which were mostly mild and transient in nature. The most common adverse effects were fatigue (15 patients, 11.7%) and poor appetite (9 patients, 7.0%). Twenty-one (16.4%) patients experienced an increased seizure frequency. Conclusions: Rufinamide appears to be a safe and effective adjuvant treatment for many cases of intractable LGS.

Original languageEnglish
Pages (from-to)288-291
Number of pages4
JournalSeizure
Volume21
Issue number4
DOIs
Publication statusPublished - 2012 May

Keywords

  • Child
  • Lennox-Gastaut syndrome
  • Rufinamide

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Rufinamide as an adjuvant treatment in children with Lennox-Gastaut syndrome'. Together they form a unique fingerprint.

  • Cite this

    Kim, S. H., Eun, S. H., Kang, H. C., Kwon, E. J., Byeon, J. H., Lee, Y. M., Lee, J. S., Eun, B. L., & Kim, H. D. (2012). Rufinamide as an adjuvant treatment in children with Lennox-Gastaut syndrome. Seizure, 21(4), 288-291. https://doi.org/10.1016/j.seizure.2012.02.006